Abstracts Archive - Page 2389 of 2425 - ACR Meeting Abstracts

Abstract Number: 509 • 2012 ACR/ARHP Annual Meeting
IL-7 and Toll-Like Receptor 7 Synergistically Increase Th1/Th17/Th22 Cytokine Secretion and Activity of B Cells
A. Bikker¹, A.a. Kruize¹, F. Redegeld², W. de Jager³, F.P.J.G. Lafeber⁴ and J.A.G. van Roon⁵, ¹Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Dept Pharmacology UU, Utrecht, Netherlands, ³Dept Immunology, UMC Utrecht, Utrecht, Netherlands, ⁴Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Rheumatology & Clinical Immunology/Lab Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: IL-7 is a potent T cell activating cytokine that has been shown to cause proliferation, survival and differentiation of T cells as well as…
Abstract Number: 470 • 2012 ACR/ARHP Annual Meeting
Concomitant Assessment of Clinical and Ultrasound Efficacy and Safety of Tocilizumab in Patients with Moderate to Severe Rheumatoid Arthritis: The Torpedo Study
Thierry Schaeverbeke¹, Philippe Gaudin², Aleth Perdriger³, Christian Roux⁴, Muriel Vray⁵, Stephanie Rouanet⁶, Ghislaine Steinberg⁷ and Fabien Etchepare⁸, ¹Service de Rhumatologie, Groupe Hospitalier Pellegrin, Bordeaux, France, ²Rheumatology Department, CHU Hôpital Sud, Grenoble Teaching Hospital, Echirolles, France, ³Rheumatology, Hôpital Sud, Rennes, France, ⁴Rheumatology, Paris Descartes University, Paris, France, ⁵Institut Pasteur, Paris, France, ⁶Medical Department, Roche, Boulogne, France, ⁷Medical department, Roche, Boulogne, France, ⁸G.H. Pitié-Salpêtrière, Paris, France
Background/Purpose: The anti-IL6-R tocilizumab (TCZ), indicated for the treatment of moderate to severe rheumatoid arthritis (RA), has demonstrated its clinical and structural efficacy in phase…
Abstract Number: 471 • 2012 ACR/ARHP Annual Meeting
Efficacy and Safety of Golimumab As Add-On Therapy to Disease-Modifying Antirheumatic Drugs
Bernard Combe¹, Bhaskar Dasgupta², Ingrid Louw³, Sarvajeet Pal⁴, Jürgen Wollenhaupt⁵, Cristiano Zerbini⁶, Andre D. Beaulieu⁷, Hendrik Schulze-Koops⁸, Patrick Durez⁹, Ruji Yao¹⁰, Nathan Vastesaeger¹¹ and Holly Weng¹⁰, ¹Hôpital Lapeyronie-Service d'Immuno-rhumatologie, Montpellier, France, ²Rheumatology, Southend University Hospital, Westcliff-on-Sea, United Kingdom, ³Panorama Medical Centre, Cape Town, South Africa, ⁴Advance Rheumatology Clinic, Hyderabad, India, ⁵Schön-Klinik, Hamburg, Germany, ⁶Centro Paulista de Investigações, Sao Paulo, Brazil, ⁷Bureau 140, Centre de Rhumatologie, St. Louis, QC, Canada, ⁸University of Munich, Munich, Germany, ⁹UCL Saint-Luc, Brussels, Belgium, ¹⁰Merck Sharp & Dohme, Kenilworth, NJ, ¹¹Merck Sharp & Dohme, Brussels, Belgium
Background/Purpose: This study evaluated golimumab (GLM) as add-on therapy in patients with active RA despite treatment with non-biologic DMARDs. Two GLM treatment strategies (subcutaneous [SC]…
Abstract Number: 472 • 2012 ACR/ARHP Annual Meeting
More Positive Expectations of Treatment with Golimumab for Rheumatoid Arthritis Are Associated with Greater Improvement in Clinical Outcomes
Bhaskar Dasgupta¹, Bernard Combe², Ingrid Louw³, Sarvajeet Pal⁴, Jürgen Wollenhaupt⁵, Cristiano Zerbini⁶, Andre D. Beaulieu⁷, Hendrik Schulze-Koops⁸, Patrick Durez⁹, W. Bensen¹⁰, V. Wolff¹¹, Ruji Yao¹², Holly Weng¹² and Nathan Vastesaeger¹³, ¹Southend University Hospital, Westcliff-on-Sea, United Kingdom, ²Hôpital Lapeyronie-Service d'Immuno-rhumatologie, Montpellier, France, ³Panorama Medical Centre, Cape Town, South Africa, ⁴Advance Rheumatology Clinic, Hyderabad, India, ⁵Schön-Klinik, Hamburg, Germany, ⁶Centro Paulista de Investigações, Sao Paulo, Brazil, ⁷Bureau 140, Centre de Rhumatologie, St. Louis, QC, Canada, ⁸University of Munich, Munich, Germany, ⁹UCL Saint-Luc, Brussels, Belgium, ¹⁰St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada, ¹¹Hospital del Salvador, Santiago, Chile, ¹²Merck Sharp & Dohme, Kenilworth, NJ, ¹³Merck Sharp & Dohme, Brussels, Belgium
Background/Purpose: Little is known about how patient and physician expectations relate to clinical outcomes. This study investigated the expectations that patients and physicians have at…
Abstract Number: 473 • 2012 ACR/ARHP Annual Meeting
The Addition of Another Disease-Modifying Anti-Rheumatic Drug to Methotrexate in Place of Infliximab Reduces the Flare Rate During 2 Years After Infliximab Discontinuation in Patients with Rheumatoid Arthritis
Hideto Kameda¹, Takahiko Kurasawa¹, Hayato Nagasawa², Koichi Amano³ and Tsutomu Takeuchi⁴, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Division of Rheumatology and Clinical Immunology, Department of Internal Medicine, Saitama Medical Ctr, Kawagoe, Japan, ³Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan, ⁴Rheumatology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: The treatment strategy for rheumatoid arthritis (RA) should be divided into remission-induction phase and its maintenance phase. To date, the usefulness of the combination…
Abstract Number: 474 • 2012 ACR/ARHP Annual Meeting
Dose Reduction in Rituximab Retreatment May Delay Achievement of Optimal Responses
Mohammed I. Sharif¹, Sudipto Das², Paul Emery³, Helen MacIver¹, Wendy Shingler¹, Philip S. Helliwell⁴, Katharina Sokoll¹ and Edward M. Vital⁵, ¹Rheumatology, Bradford Teaching Hospitals NHS Foundation Trust, Bradford, United Kingdom, ²Leeds Institute of Rheumatic & Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Medicine, Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁴PsAID taskforce, EULAR, Zurich, Switzerland, ⁵Section of Musculoskeletal Disease, NIHR Leeds Biomedical Research Unit, University of Leeds and Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: The best long-term treatment strategy for rituximab has not been established. Retreatment at a fixed interval of 6 months maintains stable disease activity1 and…
Abstract Number: 475 • 2012 ACR/ARHP Annual Meeting
Immunologic Responsiveness in Patients with Juvenile Idiopathic Arthritis On Methotrexate and Etanercept: 23 Valent Pneumococcal Vaccination
Ankur A. Kamdar¹, Patricia C. Giclas² and Barry L. Myones³, ¹Rheumatology, University of Texas Medical School at Houston, Houston, TX, ²Pediatric Allergy and Immunology, National Jewish Health, Denver, CO, ³Pediatrics, Baylor College of Medicine, Houston, TX
Background/Purpose: There is a paucity of data regarding response to vaccinations in patients with juvenile idiopathic arthritis (JIA) treated with methotrexate (MTX). It is also…
Abstract Number: 476 • 2012 ACR/ARHP Annual Meeting
Effects of Vitamin D Repletion and Maintenance Therapy On Clinical Indicators of Disease Activity in Rheumatoid Arthritis
Uzma J. Haque¹, Clifton O. Bingham III² and Susan J. Bartlett³, ¹Rheumatology, Johns Hopkins Hospital, Baltimore, MD, ²Department of Medicine, Johns Hopkins University, Baltimore, MD, ³Clinical Epidemiology, McGill University, Montreal, QC, Canada
Background/Purpose: Low Vitamin D levels are prevalent in Rheumatoid Arthritis (RA). We have previously reported that low vitamin D levels are associated with higher…
Abstract Number: 477 • 2012 ACR/ARHP Annual Meeting
Impact of Etanercept On Incident Cancer in Taiwanese Patients with Rheumatoid Arthritis
Jiunn Horng Chen¹ and Wen-Miin Liang², ¹Internal Medicine, China Medical University Hospital, Taichung City, Taiwan, ²Biostatistics Center, China Medical University, Taichung, Taiwan
Background/Purpose: The recent Taiwanese report has indicated an elevated risk of malignancy in RA patients1. Etanercept, one of the tumor necrotic factor inhibitors (TNF-I) to…
Abstract Number: 478 • 2012 ACR/ARHP Annual Meeting
Body Mass Index Negatively Influences the Response to Infliximab in Rheumatoid Arthritis
Sébastien Ottaviani¹, Anais Gardette², Emilie Quintin², Karen Dawidowicz², Ghislaine Gill², Elisabeth Palazzo³, Olivier Meyer⁴ and Philippe Dieude⁵, ¹Service de Rhumatologie, Hôpital Bichat, APHP, APHP, Paris, France, ²Rheumatology, APHP, Hopital Bichat, Paris, France, ³Hopital Bichat, Paris, France, ⁴Rheumatology, Hopital Bichat, Paris, France, ⁵Rheumatology, Rheumatology departement & INSERM U699, Paris Diderot university, APHP, Bichat hospital, Paris, France
Background/Purpose: The excess of adipose tissue in obese individuals may have immunomodulating properties and pharmacokinetics consequences. Adipose tissue is potentially involved in the regulation of…
Abstract Number: 479 • 2012 ACR/ARHP Annual Meeting
Active Immunization with TNF-Kinoid in Rheumatoid Arthritis Patients with Secondary Resistance to Tumor Necrosis Factor-Alpha Antagonists Is Safe and Immunogenic
Patrick Durez¹, Pedro Miranda², Antoaneta Toncheva³, Alberto Berman Sr.⁴, Oscar L. Rillo⁵, Yves Boutsen⁶, Tatjana Kehler⁷, Eugenia Mociran⁸, LiAn Soto Saez⁹, Bruno Fautrel¹⁰, Xavier Mariette¹¹, Panayot Solakov¹², Eleonora Lucero¹³, Tonko Vlak¹⁴, Simeon Grazio¹⁵, Ksenija Mastrovic¹⁶, Rodica Chiriac¹⁷, Géraldine Grouard-Vogel¹⁸, Olivier Dhellin¹⁸, Stéphane Ouary¹⁸, Pierre Vandepapeliere¹⁸ and Marie-Christophe Boissier¹⁹, ¹Department of Rheumatology, Université Catholique de Louvain, Brussels, Belgium, ²Universidad de Chile and Centro de Estudios Reumatologicos, Santiago de Chile, Chile, ³National Multiprofile Transport Hospital, Sofia, Bulgaria, ⁴Internal Medicine, Hospital Padilla, Tucuman, Argentina, ⁵Rheumatology, Hospital General de Agudos "Dr. E. Tornú", Buenos Aires, Argentina, ⁶UCL Mont-Godinne, Godinne, Belgium, ⁷Thalassotherapia Opatija, Opatija, Croatia, ⁸Emergency County Hospital Dr Constantin Opis, Maramures, Romania, ⁹Sociedad Medica del Aparato Locomotor SA, Santiago de Chile, Chile, ¹⁰Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, ¹¹Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France, ¹²Plovdiv, Diagnostic and Consulting Center, Plovdiv, Bulgaria, ¹³Rheumatology Unit, Padilla Hospital, Tucumán, Argentina, ¹⁴University Hospital Split, Split, Croatia, ¹⁵Clinical Hospital Center Sestre Milosrdnice, Zagreb, Croatia, ¹⁶Clinical Hospital Sveti Duh, Zagreb, Croatia, ¹⁷Rehabilitation clinical Hospital Iasi, Iasi, Romania, ¹⁸NEOVACS SA, Paris, France, ¹⁹Dept of Rheumatology, Hopital Avicenne, Bobigny, France
Background/Purpose: Blocking TNF alpha (TNFα) with monoclonal antibodies (mAbs) has been successful in the treatment of rheumatoid arthritis. However secondary resistances are frequent and impose…
Abstract Number: 480 • 2012 ACR/ARHP Annual Meeting
Etanercept Induces A Significant Decrease of Oxidative Stress and Osteoprotegerin Compared with Sdmard in Patients with Rheumatoid Arthritis
Claire I. Daien¹, Anne-Marie Dupuy Gorce², Edith Pinot², Thibault Mura³, Jean-Paul Cristol², Bernard Combe⁴ and Jacques Morel⁵, ¹Department of Rheumatology, Lapeyronie Hospital, Montpellier, France, ²Biochemistry, Hopital Lapeyronie, Montpellier, France, ³CIC, Hopital Gui De Chauliac, Montpellier, France, ⁴Rheumatology, Hopital Lapeyronie, Montpellier, France, ⁵Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France
Background/Purpose: TNF-inhibitors are known to decrease cardiovascular events in rheumatoid arthritis (RA) as compared with synthetic disease modifying anti-rheumatic drugs (sDMARD). However, mechanisms involved remain…
Abstract Number: 481 • 2012 ACR/ARHP Annual Meeting
Duration of Sustained Remission and Differences in Responce Between Medications, in Tumor Necrosis factor inhibitor Treated Rheumatoid Arthritis Patients
Jon T. Einarsson¹, Pierre Geborek², Tore Saxne³ and Meliha C. Kapetanovic⁴, ¹Dept of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden, ²Dept of Clinical Sciences Lund, Section of Rheumatology, Lund University, Lund, Sweden, ³Section of Rheumatology, Deparment of Clinical Sciences, Lund, Lund University, Lund, Sweden, ⁴Section of Rheumatology, Dept of Clinical Sciences Lund, Lund, Sweden
Background/Purpose: Remission is increasingly becoming a treatment goal in rheumatoid arthritis (RA) patients and DAS28 remission criteria are widely used, despite their limitations. The purpose…
Abstract Number: 482 • 2012 ACR/ARHP Annual Meeting
B-Lymphocyte Count Is Not Associated with an Increased Risk of Infection in Patients Treated with Rituximab for Auto-Immune Diseases
Ilias Lazarou¹, Axel Finckh², Lara Fischer³, Camillo Ribi³, Joerg Seebach³ and Pierre A. Guerne², ¹University Hospitals of Geneva, Geneva, Switzerland, ²Rheumatology, University Hospitals of Geneva, Geneva, Switzerland, ³Immunology, University Hospitals of Geneva, Geneva, Switzerland
Background/Purpose: B-Lymphocyte (B-Ly) depletion therapy with the monoclonal anti-CD20 antibody rituximab (RTX) is widely used in a variety of autoimmune (AI) diseases. The risk of…
Abstract Number: 483 • 2012 ACR/ARHP Annual Meeting
An Evaluation of Literature On Discontinuation Rates of Biologics in Rheumatoid Arthritis
Setareh A. Williams¹, Victoria Porter², Victoria Zarotsky³, Sujatha Sundaram⁴, Elisabeth Nyman⁵, Cassie K. Gregson⁶ and Paul S. J. Miller⁶, ¹AstraZeneca LP, Wilmington, DE, ²OptumInsight, Mastic Beach, NY, ³OptumInsight, Calabasas, CA, ⁴OptumInsight, Hanover, NH, ⁵AstraZeneca, Mölndal, Sweden, ⁶AstraZeneca, Macclesfield, United Kingdom
Background/Purpose: To assess reasons for biologic discontinuation or switching in the treatment of rheumatoid arthritis (RA). Methods: A text mining strategy was developed to identify, from the biomedical…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].